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Abstract
Objective: To assess the safety of VivaGelH used vaginally twice daily for 14 days among healthy, sexually-abstinent women,
aged 18–24 years in the USA and Kenya.
Design: Randomized placebo controlled trial.
Methods: Participants were randomized 2:1, VivaGel to placebo. Safety was assessed by comparing genitourinary (GU)
adverse events (AEs), colposcopy findings, vaginal lactobacilli and laboratory abnormalities by arm.
Results: Fifty-four women were enrolled; 35 in the VivaGel arm and 19 in the placebo arm. Twenty-six (74%) and 10 (53%)
women reported taking all doses of VivaGel and placebo, respectively. No grade 3 or 4 AEs, or serious AEs occurred. Twenty-
five (71%) participants in the VivaGel arm compared to 10 (53%) participants in the placebo arm had at least one grade 1 or
2 GU AE associated with product use (RR=1.4, 95% CI 0.8-2.2). All seven grade 2 GU AEs associated with product use
occurred among four women in the VivaGel arm. Vulvar and cervical erythema, cervical lesions, symptomatic BV, urinary
frequency and metrorrhagia were more common in the VivaGel arm than the placebo arm. Twenty-nine (83%) participants
in the VivaGel arm had a colposcopic finding compared to 10 (53%) participants in the placebo arm (RR=1.6, 95%CI=1.0-
2.5). Two women in the VivaGel arm prematurely discontinued product use themselves due to a reported GU AE.
Persistence of H2O2-producing and non-producing lactobacilli did not differ by study arm.
Conclusions: GU AEs and colposcopic findings consistent with mild epithelial irritation and inflammation occurred more
commonly among women in the VivaGel arm.
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Introduction
In sub-Saharan Africa, 59% of people living with HIV are
women [1], and in Kenya girls age 15–24 are six times more likely
to be HIV-infected than their male age-mates (3% prevalence for
girls versus ,0.5% for boys) [2]. Furthermore, young women are
at a particularly high risk of acquiring genital herpes caused by
herpes simplex virus type 2 (HSV-2) and other sexually
transmitted infections (STI) which promote the transmission of
HIV [3]. A strategy that encourages delayed sexual debut,
monogamy and condom use is important to control the spread
of STI/HIV, but this approach requires a level of female
empowerment and control in sexual relationships often lacking
for young women. This widespread disparity of gender power
relationships makes the development, evaluation and testing of
safe and effective topical microbicides that are effective against
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16258HIV and other STIs an urgent priority for young female
populations.
VivaGelH (3% w/w SPL7013 in CarbopolH-based aqueous gel)
is a microbicide under development by Starpharma Pty Ltd. The
active ingredient of VivaGelH is SPL7013 which belongs to the
class of macromolecules called dendrimers, characterized by a
highly branched three-dimensional architecture [4]. In vitro and
in vivo studies of this compound have shown that SPL7013 is a
potent inhibitor of HSV-2 and HIV [5–8]. SPL7013 is believed to
prevent the attachment of HIV to human T-cells by binding
glycoprotein-120 and analogously prevent the attachment of
HSV-2 to epithelial cells by binding glycoprotein-B. Toxicity
studies with 3% SPL 7013 in tissue explants, in vitro, animal and
non-human primate models have demonstrated relative safety of
this product [9]. Three percent SPL 7013, the concentration used
in this clinical trial, applied vaginally to pigtailed macaques for
four consecutive days did not lead to cervicovaginal tissue
disruption and/or friability in any of six animals, while 5% SPL
7013 led to tissue disruption and/or friability in four of six animals
[9]. A previous phase 1 trial included colposcopic evaluation in 36
healthy, sexually abstinent,18–45 year old women in Australia and
demonstrated safety and tolerance of 0.5% to 3% w/w SPL7013
gel when administered once daily for seven consecutive days [10].
The International Working Group for Microbicides recom-
mends that candidate vaginal microbicides be evaluated in
populations with different characteristics [11]. This expanded
phase 1 study serves that purpose, in that it complements the other
clinical studies conducted to date. The primary objective of this
study was to assess the safety and tolerability of VivaGelH (3% w/
w SPL7013 Gel) versus placebo (same gel without SPL7013) when
applied vaginally two times daily for 14 consecutive days among
healthy, HIV and STI free, sexually abstinent, 18–24 year old
women in the U.S. and in Kenya.
Methods
Ethics Statement
The study protocol and informed consent forms were approved by
the Committee on Human Research at UCSF and the National
Ethical Review Committee at KEMRI. Safety oversight was provided
by Independent Safety Monitors and a Safety Monitoring Committee.
Objectives
Safety was assessed by comparing the incidence of adverse events
(AE), including genitourinary (GU) clinical signs and symptoms,
colposcopic findings of the genital tract, renal and liver function,
systemic absorption of SPL7013, and vaginal microflora among
participants randomized to VivaGelH (3% w/w SPL7013 in a
Carbopol-based aqueous formulation) and those randomized to
placebo (Carbopol-based aqueous formulation with 0% w/w
SPL7013). The Female Genital Grading Table for Use in
Microbicide Studies (November 2007, Addendum 1 to the Division
of AIDS (DAIDS) Table for Grading the Severity of Adult Adverse
Experiences)was used to gradeGUabnormalities,and the definition
ofGUAEsusedinthe study were any AEsidentified inthistable.All
AEs had their relationship to product use assessed as either
associated (event is temporally related to the administration of
product use and no other etiology explains the event) or not
associated (the event is temporally independent of the study product
and/or the event appears to be explained by another etiology). The
WHO/CONRAD colposcopy manual [12] was used to define
colposcopic findings, and highly trained staff at both sites performed
the speculum examinations. The Division of Microbiology and
Infectious Diseases Adult Toxicity Table (December 2004) was used
to grade serum chemistry, hematology, and other abnormalities.
Clinical signs and symptoms were assessed at enrollment, and 2, 7,
14and21days following initiation of product use; vaginalmicroflora
was assessedatenrollment and 7,14,and 21 daysfollowing initiation
of product use, and serum chemistry and hematology were assessed
at enrollment and 14 and 21 days following initiation of product use.
Participants were discontinued from study product by study staff if a
grade 3 or higher AE was reported or discovered during clinical
examinationduringfollow-up,oriftheparticipantwasnon-adherent
to the study protocol. Tolerability was assessed by comparing the
number of participants in the VivaGelH and placebo arms who
discontinued product use themselves due to an overt adverse event.
Adherent participants were defined as those who administered the
study product twice daily over 14 consecutive days for a total of 28
doses, or those who missed one or two doses on one or two days, but
administered these missed doses over one to two additional days to
complete the 28 doses.
Design
This was a Phase 1, placebo-controlled, randomized, double
blind, study in sexually-abstinent young women conducted at the
Pediatric Clinical Research Center at the University of California,
San Francisco (UCSF), USA and the Research Care and Training
Program unit of the Center for Microbiology Research at the
Kenya Medical Research Institute (KEMRI) in Kisumu, Kenya.
Procedures were reviewed by investigators and study personnel at
both sites prior to and during study implementation.
Selection of subjects
Volunteers were enrolled if they were 18-24 years of age and in
good health, had regular menstrual cycles of at least 25 days in
length, sexually experienced but willing to be sexually abstinent
one week prior to enrollment and throughout the 21 days of study
participation, not breastfeeding, not pregnant and not within 3
months of last pregnancy outcome, no history of intermenstrual
bleeding during the prior three months, and provided written
informed consent for study participation. Volunteers who met any
of the following criteria were not enrolled: clinically detectable
genital epithelia disruption; positive test for human chorionic
gonadotropin (hCG), urinary tract infection (UTI), HIV antibod-
ies, HSV-2 antibodies, syphilis, vaginal candidiasis, symptomatic
bacterial vaginosis (BV), vaginal Nugent score $7 at screening
visit, cervicovaginal Trichomonas vaginalis, Neisseria gonorrhoeae, or
Chlamydia Trachomatis at screening or enrollment visits; abnormal
cervical cytology (Pap smear); and greater than grade 1 serum
chemistry or hematology findings. In addition, exclusion criteria
also included allergy to any known component of study product or
latex; starting a new long-acting contraceptive treatment (e.g.
depomedroxyprogesterone) within the past 3 months; history of
recurrent vaginal infections (.2 in past 12 months); active
uncontrolled medical condition; acute clinically significant illness
within the past 30 days; received a new systemic or topical
medication within 14 days prior to using the study product; or
currently using any other investigational drug.
Study procedures
Each volunteer was seen in six scheduled visits. At the first visit
(screening), written informed consent was obtained as well as a
medical history. A urine sample was obtained to test for hCG and
for urinalysis if the volunteer was symptomatic for a UTI. HIV
and STI counseling was performed, and a blood sample was
collected to test for HIV, HSV-2, syphilis, as well as hematology
testing, and liver and renal function testing. A physical
examination including pelvic examination was performed. The
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copy, as well as vaginal pH testing, vaginal wet mount for
candidiasis, bacterial vaginosis (BV) by Amsel’s criteria, and
collection of vaginal swabs for lactobacillus culture and Nugent’s
Gram stain testing for BV [13] and cervicovaginal swabs
specimens for T. vaginalis, N. gonorrhoeae, C. trachomatis testing, and
a Pap smear. The volunteer was instructed not to use vaginal
products and to abstain from sexual intercourse during the 7 days
prior to the second visit.
The second visit (enrollment (Day 0)) was scheduled to fall within
5-14 days after the first day of the next menses. Participants were
provided with post-test counseling and screening test results.
Eligibility criteria were reviewed, a urine specimen was taken for
pregnancy testing and, if the volunteer was symptomatic, for
urinalysis. A review of symptoms was conducted, and a pelvic exam
including naked eye examination, colposcopy, vaginal pH and
vaginal wet mount were performed. If the volunteer continued to
meet the eligibility criteria, she was enrolled and additional vaginal
specimens were collected for lactobacillus culture, Gram stain and
prostate specific antigen (PSA) testing [14], and cervicovaginal
swabs specimens for T. vaginalis, N. gonorrhoeae, and C. trachomatis
testing. A blood sample was collected for hematology, liver and
renal function testing, and to test for SPL7013 drug levels.
The randomization scheme was developed by a UCSF
statistician not otherwise directly involved with study participants.
Subjects were randomized in a 2:1 VivaGelH to placebo ratio. The
allocation sequence was generated using the pseudo-random
number generator of the statistical software program SAS/STAT
software (SAS Inc., version 9.13, Cary, NC) and used randomly
varied permuted block sizes. Individual assignments were
concealed in sequentially numbered, sealed, study drug kits.
Randomization was stratified by site as determined on the date of
enrollment. The participants, investigators, sponsor, and study
staff did not know which gel a participant received, nor did they
know the block size.
Enrolled participants received 14 identical, pre-filled, single-use
applicators containing 3.5 g of one of the study products:
VivaGelH or placebo gel. Fourteen additional applicators were
given to participants at their Day 7 visit. Each applicator was over-
wrapped in a sealed plastic envelope. The first application of study
product was supervised in the clinic. The participant was
instructed to insert the study product two times per day (one
applicator in the morning and a second applicator in the evening)
and to place the used applicator back into the overwrap and plastic
envelope, and return them to the study clinic. The participant was
also instructed to not use any other vaginal products and to abstain
from sexual intercourse. She was given a diary card on which to
record the date and time of product application, any symptoms
experienced, and episodes of intercourse. In order to avoid having
the gel interfere with the colposcopic assessments and laboratory
testing, participants were instructed to not insert study gel at least
6 hours before a scheduled follow-up visit.
Participants returned to the clinic for follow-up visits on Day 2,
Day 7, Day 14 and Day 21 following the enrollment visit. During
follow-up visits, study staff collected used applicators, which were
tested for exposure to vaginal mucus using trypan blue staining
technique [15]. A review of symptoms, a pelvic exam including
naked eye examination, and collection of vaginal samples for pH,
wet mount, PSA (or Y-chromosome DNA), lactobacillus culture,
and Gram stain were collected at each follow-up visit. Multiplex
PCR testing for Haemophilus Ducreyi, Treponema pallidum, and HSV-2
was performed at each follow-up visit on participants with genital
ulcers. Colposcopic examinations were conducted on the Day 2,
Day 14, and Day 21 follow-up visits. In addition, participants with
clinical GU signs or who reported GU symptoms on Day 7
received a colposcopic examination during that visit. During the
Day 14 and Day 21 follow-up visit, urine was collected for
pregnancy testing, and a blood sample was collected for
hematology, liver and renal function testing, and to test for
SPL7013 drug levels.
Lab methods
Pregnancy was tested by rapid urine hCG assays (in Kisumu:
Quidel QuickVue One-Step, Santa Clara, CA; in San Francisco:
Mainline Confirms Pregnancy Rapid Assay, Mainline Technolo-
gy, Inc, Ann Arbor, MI). Urine was tested by urine dipstick for
evidence of urinary tract infection (Bayer Multistix, Deerfield, IL).
HIV antibody testing was conducted using standardized algo-
rithms at each site (in Kisumu: two different rapid tests were
conducted (Abbott Determine HIV-1 and -2, Abbot Park, IL; and
Unigold Rapid Assay, Trinity Biotech plc, Bray, Ireland), with a
confirmatory ELISA (BioMerieux Vironostika HIV Uni-Form II
Antigen/Antibody ELISA, Marcy l’Etoile, France); in San
Francisco, an ELISA (BioMerieux Vironostika HIV Uni-Form II
Antigen/Antibody ELISA) was conducted, with confirmatory
Western Blot (Genetic Systems Reflex Western Blot by Bio-Rad,
Hercules, CA) for ELISA positives). Syphilis was tested by rapid
plasma reagin (Becton Dickenson Macrovue RPR, Franklin Lakes,
NJ) with a confirmatory agglutination test (in Kisumu: Biokit
Syphagen T. pallidum Hemaglutination, Barcelona, Spain; in San
Francisco: Fujirebio Serodia T. pallidum Passive Particle Aggluti-
nation, Tokyo, Japan). HSV-2 antibody testing was conducted
using an ELISA (Focus Technologies HSV-2 IgG ELISA, Cypress,
CA). Bacterial vaginosis was determined through the evaluation of
Gram stained vaginal smears using Nugent’s criteria [13]. Vaginal
swabs collected at enrollment and day 2 were evaluated for the
presence of PSA on the ARCHITECT System (Abbott Labora-
tories, Abbott Park, Illinois) and vaginal samples with PSA
concentrations $1 ng/mL were considered positive [14]. Vaginal
swabs collected at days 7, 14, 21 were evaluated for sperm-derived
Y chromosomal DNA sequences (Yc) using a Real-Time PCR
assay (Roche Diagnostics, Indianapolis, Indiana) [16]. Cervico-
vaginal swabs were evaluated for T. vaginalis, N. gonorrhoeae, and C.
trachomatis by Gen-Probe Aptima Combo 2 Assay (Gen-Probe Inc,
San Diego, CA). Pap smears were conducted on cervical
specimens (ThinPrep pap test, Cytyc Corporation, Marlborough,
MA). Returned used applicators were tested for exposure to
vaginal mucus using trypan blue staining technique [15]. Genital
ulcers were swabbed and tested for H. ducreyi, T. pallidum, and
HSV-2 by multiplex PCR. Vaginal cultures for semiquantitative
microbiological assessment were obtained with polyester-tipped
swabs and immediately placed in Port-A-Cul
TM anaerobic
transport tubes (Becton-Dickinson, Cockeysville, MD) and evalu-
ated for the presence of lactobacillus and the production of
hydrogen peroxide. Serum was tested for liver and kidney function
and whole blood was used for complete blood counts and
differentials. Pharmacokinetic analysis for plasma levels of
SPL7013 was conducted by Starpharma using a capillary
electrophoresis bioanalytical method employing a Micellar
Electrokinetic Chromatography technique that had been devel-
oped and validated by Starpharma and which has a lower limit of
quantitation for SPL7013 of 30 nM (0.5 mg/mL).
Analysis of study outcomes
The planned sample size of 60 participants was based on
recommendations stated in an update from the International
Working Group on Microbicides [11]. Data entry, data manage-
ment and statistical analysis were carried out by UCSF using SAS
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population was defined as participants who were randomized,
and received at least one dose of study product, irrespective of
whether they completed the study. Analyses for primary safety
study endpoints were based on treatment group-specific summaries
of frequency, severity and relationship to product use of AEs. AEs
were tabulated both as frequencies and proportions of participants
experiencing at least one event, and overall frequency of observed
events pooled over participants. Within-participant changes in
vaginal flora and laboratory parameters were also summarized for
each treatment group. Formal comparisons between treatment
groups in these outcomes were unadjusted and summarized using
relative risks and associated 95% confidence intervals (CI).
Results
Enrollment and participant disposition
The planned sample size was 60 participants. However, on
October 18, 2007 the study sponsor, the Division of Microbiology
and Infectious Diseases (DMID), National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH)
made the decision to close the trial based on the belief that
sufficient outcome data had been generated. This assessment was
made following the pausing of a parallel study, Microbicides Trial
Network (MTN)-004 sponsored by the Division of AIDS (DAIDS),
NIAID, NIH, which had recently started to enrol participants in to
a similarly designed trial of VivaGelH twice daily for 14 days at two
sites, one in Tampa, Florida, and one in San Juan, Puerto Rico.
After enrolling the first seven participants, the medical officer for
MTN-004 decided to pause that trial so that an interim analysis of
the data could be conducted, following several reports of
genitourinary adverse events. The medical officer and project
officer at DMID overseeing our trial made a decision based on this
information, and the fact that we had enrolled 54 of the 60
intended participants, to close our trial. Of note, the MTN-004
trial protocol was subsequently amended, and the trial was
restarted and completed [17]. Thus, a total of 54 women were
enrolled in our trial, and among those, 5 women who were in
active follow-up at the time the decision to close the trial was made
were prematurely discontinued from study product and followed
through their exit visit.
Of the 54 women, 35 women were enrolled in the VivaGelH
arm and 19 in the placebo arm (Figure 1). One woman in each
arm was lost to follow-up. Follow-up rates were high (89%–96%)
at each visit, and were comparable between treatment arms. The
mean age was 20.8 years in the VivaGelH arm vs. 20.9 years in the
placebo arm (Table 1). Lifetime number of sexual partners was 2.6
(SD =2.7) and 4.1 (SD =5.9), and the number of sexual partners
in the last 3 months was 0.8 (SD =0.5) and 0.9 (SD =0.7) in the
VivaGelH arm and placebo arm, respectively (Table 1).
Adherence and tolerability
Adherence data included participants who discontinued study
product for any reason, including those instructed to discontinue
study product by study staff. Overall, adherence was higher in the
VivaGelH arm compared to the placebo arm; twenty-six (74%)
participants and 10 (53%) participants, respectively, reported
taking all 28 doses of VivaGelH and placebo (Table 2). Adherence
according to the protocol was similar between the VivaGelH
(7 (64%)) and placebo (4 (57%)) arms at the San Francisco site,
while at the Kisumu site adherence was greater among
participants in the VivaGelH arm (19 (79%)) in comparison to
the placebo arm (6 (50%)).
No participant was discontinued from study product by study
staff due to an AE. Two (5.7%) participants in the VivaGelH arm
prematurely discontinued themselves from study product due to
concerns with symptoms; one reported discontinuing study
product due to gross hematuria after taking 14 doses, and the
other reported discontinuing study product due to pain during last
product insertion, cramping and gel leakage after taking 22 doses
(Table 2). In addition, 2 (5.7%) participants in the VivaGelH arm
and 4 (21.0%) in the placebo arm did not take all 28 doses due to
product discontinuation by study staff; 3 due to early closure of the
study, and 3 due to protocol deviations by study staff (Table 2).
Four (11.4%) participants in the VivaGelH arm and 4 (21.1%) in
the placebo arm did not take all 28 doses per protocol due to other
reasons (Table 2). At the San Francisco site a lower proportion of
participants took one or more of the assigned VivaGelH doses for
$8 days (82%) in comparison to the placebo (100%), while at the
Kisumu site a greater proportion of participants in the VivaGelH
arm took one or more of the assigned doses for $8 days (92%) in
comparison to the placebo (67%). Dosing information is
unavailable for 1 (2.9%) participant in the VivaGelH arm (San
Francisco) and 1 (5.3%) in the placebo arm (Kisumu) who were
lost to follow-up after enrollment.
Study participants returned 99% of used applicators to the study
clinic. Of the returned used applicators, 97% of both the VivaGelH
and placebo applicators stained positive for exposure to vaginal
mucus, and staining results did not vary meaningfully by site (99%
and 97% of used applicators stained positive in San Francisco and
Kisumu, respectively).
Despite repeated counseling at each study visit to abstain from
sexual intercourse for 7 days prior to enrollment and throughout
the study period, one participant in the VivaGelH arm reported
having sexual intercourse during the study period. In addition, 4
(11.4%) participants in the VivaGelH arm and 3 (15.7%)
participants in the placebo arm tested positive for exposure to
sperm by PSA or Y-chromosome testing which was performed
after the conclusion of the trial; one participant at enrollment, two
at Day 7, three at Day 14, and one at Day 21 (data not shown).
Genitourinary Adverse Events
No grade 3 or 4 AEs, or SAEs were detected. Over the course of
the trial, 106 grade 1 or 2 GU AEs (associated and not-associated
with product use) were reported by 29 (83%) participants in the
VivaGelH arm compared to 33 reported in 11 (58%) participants
in the placebo arm. The relative risk (RR) comparing these
proportions between the VivaGelH and placebo arms was 1.4
(95% CI 0.95-2.2) (Table 3). Limiting the analysis only to GU AEs
associated with product use, 83 grade 1 or 2 GU AEs were
reported by 25 (71%) participants in the VivaGelH arm compared
to 20 reported in 10 (53%) participants in the placebo arm. The
relative risk comparing these proportions between the VivaGelH
and placebo arms was 1.4 (95% CI 0.8-2.2) (Table 3). Vulvar and
cervical erythema, cervical lesions, clinically diagnosed symptom-
atic BV, urinary frequency, metrorrhagia, and unexplained
infrequent bleeding were more common among participants in
the VivaGelH arm than the placebo arm (see Table S1). Vaginal
and vulval pain was reported more frequently in the placebo arm
than the VivaGelH arm (see Table S1). During the second and
third weeks of follow-up (i.e. Days 8–14 and Days 15–24), but not
during the first week of follow-up (i.e. Days 0–7) the proportion of
women with a GU AE associated with product use was greater
among women in the VivaGelH arm than in the placebo arm
(Table 3). Two participants in the VivaGelH arm had grade 1
perianal ulcers, both of which were negative for HSV-2, H. ducreyi,
and T. pallidum. Although relatively rare, all grade 2 GU AEs
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participants in the VivaGelH arm at the San Francisco site.
At the San Francisco site a slightly greater proportion of
participants in the placebo arm compared with the VivaGelH arm
reported at least one GU AE associated with study product. A total
of 52 GU AEs considered associated with study product were
reported by 10 (91%) participants in the VivaGelH in comparison
to 31 GU AEs reported by 7 (100%) in the placebo arm among
participants at the San Francisco site. In contrast, among
participants at the Kisumu site a greater proportion of participants
had at least one GU AE associated with product use in the
VivaGelH arm: 31 GU AEs were reported in 15 (63%) participants
in comparison to the placebo arm where 6 GU AES were reported
in 3 (25%) participants at the Kisumu site. It is of note that
participants at the San Francisco site recruited half the number of
participants than Kisumu, yet reported considerably higher
numbers of GU AEs. Specifically, abnormal vaginal discharge
(not including gel leakage) was reported more commonly among
women enrolled in San Francisco (83%) than in Kisumu (19%),
although the proportion of women reporting abnormal vaginal
discharge (not including gel leakage) was similar among women in
the VivaGelH and placebo arms in San Francisco (82% vs. 86%,
respectively) and Kisumu (17% vs. 8%, respectively).
Colposcopy findings
Over the course of the trial, 29 (83%) participants in the
VivaGelH arm had 77 colposcopic findings compared to 10 (53%)
participants having 20 such findings in the placebo arm (Table 4).
The proportion of women who had a colposcopic finding was
significantly greater among women in the VivaGelH arm than in
the placebo arm (83% vs. 53%; RR=1.6, 95% CI 1.0-2.5).
Colposcopy findings were designated as either potentially related
or unrelated to speculum insertion. In the VivaGelH arm 16 (46%)
women had 26 colposcopic findings potentially related to
Figure 1. Flow of participants.
doi:10.1371/journal.pone.0016258.g001
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potentially related findings in the placebo arm. In regards to
colposcopy finding unrelated to speculum insertion 21 (60%)
participants had 51 findings in the VivaGelH arm compared to 8
(42%) participants with 13 findings in the placebo arm. Overall,
the proportion of women with at least one colposcopic finding was
similar across study sites; 79% and 91% of women in the VivaGelH
arm compared to 50% and 57% of women in the placebo arm in
Kisumu and San Francisco, respectively had at least one
colposcopic finding during follow-up. In this study, the majority
(78/81 (97%)) of colposcopy findings were superficial. One woman
in the VivaGelH arm had two deep epithelial lesions while one
woman in the placebo arm had a single deep epithelial disruption
during follow-up (Table 4).
Table 1. Sociodemographic and sexual history by study arm and site.
VivaGelH (SPL7013) Placebo
SF Kisumu All SF Kisumu All
N=11 (%) N=24 (%) N=35 (%) N=7 (%) N=12 (%) N=19 (%)
Race/Ethnicity
American Indian/Alaska Native 0 0 0 0 0 0
Asian 3 (27%) 0 3 (8.5%) 0 0 0
Native Hawaiian/Other Pacific
Islanders
000 0 0 0
Black/African American 0 0 0 1 (14%) 0 1
White 8 (73%) 0 8 (23%) 5 (71%) 0 5
Other racial
category
0 0 0 1 (14%) 0 1
African (Kenyan) 0 24 (100%) 24 (68.5%) 0 12 (100%) 12
Age (years) 21.6 (2.2) 20.5 (1.5) 20.8 (1.8) 21.7 (1.6) 20.4 (1.7) 20.9 (1.8)
Lifetime number of sexual partners (mean, SD) 4.7 (4.0) 1.6 (0.8) 2.6 (2.7) 8.1 (8.6) 1.8 (0.8) 4.1 (5.9)
Number of sexual partners last 3 mo (mean, SD) 0.9 (0.3) 0.8 (0.5) 0.8 (0.5) 1.1 (1.1) 0.8 (0.5) 0.9 (0.7)
doi:10.1371/journal.pone.0016258.t001
Table 2. Product adherence and tolerability by treatment group as per protocol definitions.
VivaGelH (SPL7013) Placebo
N( % )
Number of
doses taken N (%)
Number of
doses taken
All 28 doses taken as defined per protocol 26 (74.2) 10 (52.6)
Premature product discontinuation by study staff 2 (5.7) 4 (21.0)
Adverse Event 0 -- -- 0 -- --
Closure of trial 1 (2.9) 4 2 (10.5) 7,14
Protocol deviation 1* (2.9) 10 2* (10.5) 11,24
Tolerability: Premature product discontinuation by study
participant due to reported adverse event
2 (5.7) 0 --
Gross hematuria 1
{ (2.9) 14 0 -- --
Pelvic pain and cramping, leakage of gel 1 (2.9) 22 0 -- --
Imperfect adherence per protocol for other reason 4 (11.4) 4 (21.1)
Participant forgot 1 (2.9) 26 2 (10.5) 24, 27
{
Participant started menses 1 (2.9) 25 1 (5.3) 24
Participant misplaced applicator 1
{ (2.9) 27 1 (5.3) 27
Participant took 3 doses on one day (not per protocol) 1 (2.9) 27 0 -- --
Lost-to-follow-up 1 (2.9) -- 1 (5.3) 13
*One enrolled participant was later found to not meet eligibility criteria and was subsequently discontinued from product use, one enrolled participant was erroneously
thought to not meet eligibility criteria and was discontinued from product use, and one participant was discontinued from product use by the site PI after completing
her Day 14 visit.
{These participants were subsequently discontinued from product due to closure of trial.
{This participant took all 28 doses in 16 days, but missed one or both doses on three days, and thus was not adherent per the protocol definition.
doi:10.1371/journal.pone.0016258.t002
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Ninety seven percent and 95% of participants in the VivaGelH
and placebo arms, respectively had lactobacillus sp. present at
enrollment. Throughout the course of the trial 86% of participants
in the VivaGelH arm and 68% of participants in the placebo arm
had lactobacilli present at every visit, with the majority of women
found with H2O2-non-producing lactobacilli at every visit (63%
among women in the VivaGelH arm and 58% among women in
the placebo arm). Persistence of H2O2-producing and H2O2-non-
producing lactobacilli was common throughout the course of the
trial, and did not differ by study arm. In general, lactobacillus
status (presence/absence) was stable in women during the
treatment period and post-dosing phase. Five (9%) participants
had BV diagnosed by Nugent’s criteria at enrollment (3 (9%)
participants in the VivaGelH group, and 2 (11%) in the placebo
group, all at the Kisumu site). In all cases, BV resolved after 7 days
of antibiotic treatment according to local standard of care. The
onset of symptomatic BV diagnosed by Amsel’s criteria during
follow-up was found among 4 (11%) participants who were all in
the VivaGelH arm; two of these cases of BV were among
participants from Kisumu who had enrolled in the study with
asymptomatic BV by Nugent’s criteria.
Non-genitourinary adverse events and laboratory
findings
Nervous system and gastrointestinal disorders were the most
common non-GU AEs by organ system. Except for headache,
which was morecommon in participants in the VivaGelH arm, non-
GU AEs did not appear different between study groups. AEs due to
changes in serum chemistry and liver and renal panels occurred
infrequently and appeared fairly balanced between the two arms of
the trial (Table 3). No participant had a positive pregnancy test.
SPL7013 was not detected in the plasma of any participant.
Discussion
This study assessed the safety and tolerability of VivaGelH
versus placebo gel when used vaginally twice a day for 14 days in
18 to 24 year old women in San Francisco and Kisumu. GU AEs
were common and occurred in both arms; 83% of participants in
the VivaGelH arm and 58% of participants in the placebo arm
experienced at least one grade 1 or 2 GU AE. Overall, GU AEs
judged to be associated with product use were more common
among participants in the VivaGelH arm than the placebo arm.
These AEs were predominantly mild in nature (grade 1) and were
self-limiting. All grade 2 GU AEs that were associated with
product use occurred in four women in the VivaGelH arm at the
San Francisco site. Superficial colposcopic abnormalities were also
common in both arms and these findings were detected more
commonly among participants in the VivaGelH arm. Vaginal flora
was not adversely affected by study product and there were no
significant changes to colonization with lactobacillus spp. Changes in
serum chemistry and renal and liver function tests occurred
infrequently during follow-up across both treatment arms and are
unlikely to be related to study treatment since it was also found
that there was no evidence of systemic absorption of SPL7013.
There were no grade 3 or 4 AEs. Two participants in the
VivaGelH arm discontinued themselves from study product during
follow-up due to a self-reported GU AE. No participant was
discontinued from study product by the study staff due to an AE.
The proportion of women with a GU AE associated with
product use was greater among those randomized to the VivaGelH
arm in comparison to the placebo arm among participants
enrolled at the Kisumu site but not at the San Francisco site. The
Kisumu site enrolled twice as many participants as the San
Francisco site, and with a 2:1 randomization scheme, the number
of women assigned to the placebo arm was relatively small at each
site. Adherence in the VivaGelH group was higher than in the
placebo group at the Kisumu site, contributed in part by the early
closure of the study and the discontinuation of study product in a
greater proportion of those randomized to the placebo arm. Thus
it is possible that exposure to fewer doses of placebo in comparison
to VivaGelH among participants at the Kisumu site may have
contributed to the difference in the incidence of GU AEs. Both
VivaGelH and the placebo are carbopol-based aqueous gels. Thus,
if carbopol or an excipient in the gel led to GU AEs, it is possible
that the differences in GU AEs observed between the VivaGelH
and placebo arms may in part be due to differential exposure to
the investigational product between the study arms in Kisumu.
Alternatively, young women in Kisumu might be more susceptible
to epithelial irritation in the genital tract perhaps in relation to
differences in vaginal flora or increased immune activation in their
genital mucosa [18]. Furthermore, imperfect adherence to product
per protocol in the VivaGelH (74%) and placebo (53%) arms may
have resulted in an underestimation of the true risk of AEs
associated with twice daily product use over 14 days.
Results of this trial are consistent with previously published
phase 1 vaginal microbicide studies among sexually abstinent
Table 3. The number of participants that experienced at least one, and the total number of genitourinary (GU) and laboratory
adverse events* by treatment group, initiation day of AE, and association with study product.
VivaGelH (SPL7013) (N=35) Placebo (N=19)
assoc. not assoc. total assoc. not assoc. total
%( N) TN %( N) TN %( N) TN %( N) TN %( N) TN %( N) TN
GU and Lab AEs, total 83 (29) 94 57 (20) 27 91 (32) 121 74 (14) 28 58 (11) 16 79 (15) 44
GU AEs, total 71 (25) 83 51 (18) 23 83 (29) 106 53 (10) 20 47 (9) 13 58 (11) 33
During days 0–7 46 (16) 40 40 (14) 16 60 (21) 56 42 (8) 11 32 (6) 8 58 (11) 19
During days 8–14 37 (13) 29 6 (2) 2 40 (14) 31 21 (4) 5 11 (2) 2 32 (6) 7
During days 15–24{ 29 (10) 14 9 (3) 5 34 (12) 19 16 (3) 4 11 (2) 3 26 (5) 7
N= number of women with at least one finding; TN = total number of findings.
*Adverse events that did not occur are not listed.
{Includes 11 events on Day 22 and one each on Days 23 and 24.
doi:10.1371/journal.pone.0016258.t003
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the phase 1 trial of once daily dosing for seven days of SPL7013,
GU AEs considered potentially product-related were all mild and
reported by 5 out of 25 (20%) women receiving VivaGelH (0.5%,
1.0% or 3.0%) and 2 (17%) of 12 women receiving placebo gel
[10]. In published reports of other candidate vaginal microbicides
the proportion of participants who experienced a GU AE has
ranged from 14% to 87% [19–25]. To our knowledge, this is one
of the first published studies to use the newly developed toxicity
table to grade GU AEs in microbicide clinical trials which could
theoretically have contributed to the high proportion of women
found to experience GU AEs in this study. It is unlikely that the
number of GU AEs reported was due to the young age of our
participants and this is supported by a recently published study
that found that older age was positively correlated with the
proportion of participants with a genital finding in another
microbicide trial [26]. The high rate of reported AEs and
colposcopic findings in the placebo arm may suggest that the
vehicle itself may have caused mild irritation. In addition,
participants in San Francisco reported a greater incidence of
AEs in comparison to participants in Kisumu. This finding could
have arisen from a difference in perception of AEs, for example
women in San Francisco reported more abnormal vaginal
discharge than women in Kisumu, or may represent biological
differences between these distinct populations. Regardless, this
finding suggests the importance of conducting multisite trials in
different populations to help evaluate product safety.
The strengths of this study include the double-blind placebo
controlled design, and the inclusion of biomarkers to corroborate
self-reported use of study product and sexual abstinence. The
study population was limited to women aged 18–24 years as they
are in greatest need of a microbicide to prevent HIV and STIs;
however, these findings may not be generalizable to older age
groups. By simultaneously conducting this study in the U.S. and
Kenya we have collected safety data in populations of varying
characteristics, an important step in the clinical development of
any vaginal microbicide.
GU AEs and colposcopic findings consistent with mild genital
epithelial irritation and inflammation occurred more commonly in
the VivaGelH arm compared with placebo gel when the products
were used twice daily for 14 days. Whether the findings from this
study translate into safety concerns for this product cannot be
ascertained entirely from this study, but should be assessed in
conjunction with all the available preclinical and clinical data.
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